0 11 Salicylates salicylate NNS 12 19 inhibit inhibit VBP 20 46 lipopolysaccharide-induced lipopolysaccharide-induced JJ 47 62 transcriptional transcriptional JJ 63 73 activation activation NN 74 76 of of IN 77 80 the the DT 81 87 tissue tissue NN 88 94 factor factor NN 95 99 gene gene NN 100 102 in in IN 103 108 human human JJ 109 118 monocytic monocytic JJ 119 124 cells cell NNS 124 125 . . . 127 134 Binding binding NN 135 137 of of IN 138 144 plasma plasma NN 145 151 Factor factor NN 152 160 VII/VIIa VII/VIIa NNP 161 163 to to TO 164 167 the the DT 168 174 tissue tissue NN 175 181 factor factor NN 182 183 ( ( ( 183 185 TF TF NNP 185 186 ) ) ) 187 195 receptor receptor NN 196 205 initiates initiate VBZ 206 209 the the DT 210 221 coagulation coagulation NN 222 230 protease protease NN 231 239 cascades cascade NNS 239 240 . . . 241 243 TF TF NNP 244 254 expression expression NN 255 257 by by IN 258 269 circulating circulate VBG 270 279 monocytes monocyte NNS 280 282 is be VBZ 283 293 associated associate VBN 294 298 with with IN 299 309 thrombotic thrombotic JJ 310 313 and and CC 314 326 inflammatory inflammatory JJ 327 340 complications complication NNS 341 343 in in IN 344 345 a a DT 346 353 variety variety NN 354 356 of of IN 357 365 diseases disease NNS 365 366 . . . 367 382 Transcriptional transcriptional JJ 383 393 activation activation NN 394 396 of of IN 397 400 the the DT 401 406 human human JJ 407 409 TF tf NN 410 414 gene gene NN 415 417 in in IN 418 427 monocytic monocytic JJ 428 433 cells cell NNS 434 441 exposed expose VBN 442 444 to to TO 445 454 bacterial bacterial JJ 455 473 lipopolysaccharide lipopolysaccharide NN 474 475 ( ( ( 475 478 LPS LPS NNP 478 479 ) ) ) 480 482 is be VBZ 483 491 mediated mediate VBN 492 494 by by IN 495 502 binding binding NN 503 505 of of IN 506 515 c-Rel/p65 c-rel/p65 NN 516 528 heterodimers heterodimer NNS 529 531 to to TO 532 533 a a DT 534 539 kappa kappa NN 540 541 B B NNP 542 546 site site NN 547 549 in in IN 550 553 the the DT 554 556 TF TF NNP 557 565 promoter promoter NN 565 566 . . . 567 571 Here here RB 571 572 , , , 573 575 we we PRP 576 582 report report VBP 583 587 that that IN 588 589 a a DT 590 596 family family NN 597 599 of of IN 600 617 anti-inflammatory anti-inflammatory JJ 618 624 agents agent NNS 624 625 , , , 626 631 known know VBN 632 634 as as IN 635 638 the the DT 639 650 salicylates salicylate NNS 650 651 , , , 652 661 inhibited inhibit VBD 662 665 LPS LPS NNP 666 675 induction induction NN 676 678 of of IN 679 681 TF TF NNP 682 690 activity activity NN 691 694 and and CC 695 697 TF tf NN 698 702 gene gene NN 703 716 transcription transcription NN 717 719 in in IN 720 725 human human JJ 726 735 monocytes monocyte NNS 736 739 and and CC 740 749 monocytic monocytic JJ 750 755 THP-1 thp-1 NN 756 761 cells cell NNS 762 764 at at IN 765 775 clinically clinically RB 776 784 relevant relevant JJ 785 790 doses dose NNS 790 791 . . . 792 803 Furthermore furthermore RB 803 804 , , , 805 811 sodium sodium NN 812 822 salicylate salicylate NN 823 830 blocked block VBD 831 834 the the DT 835 846 LPS-induced lps-induced JJ 847 858 proteolytic proteolytic JJ 859 870 degradation degradation NN 871 873 of of IN 874 875 I i NN 876 881 kappa kappa NN 882 883 B B NNP 884 889 alpha alpha NN 889 890 , , , 891 896 which which WDT 897 906 prevented prevent VBD 907 910 the the DT 911 918 nuclear nuclear JJ 919 932 translocation translocation NN 933 935 of of IN 936 945 c-Rel/p65 c-rel/p65 NN 946 958 heterodimers heterodimer NNS 958 959 . . . 960 962 In in IN 963 971 contrast contrast NN 971 972 , , , 973 976 two two CD 977 982 other other JJ 983 995 nonsteroidal nonsteroidal JJ 996 1013 anti-inflammatory anti-inflammatory JJ 1014 1019 drugs drug NNS 1019 1020 , , , 1021 1030 ibuprofen ibuprofen NN 1031 1034 and and CC 1035 1047 indomethacin indomethacin NN 1047 1048 , , , 1049 1052 did do VBD 1053 1056 not not RB 1057 1064 inhibit inhibit VB 1065 1068 LPS lps NN 1069 1078 induction induction NN 1079 1081 of of IN 1082 1085 the the DT 1086 1088 TF TF NNP 1089 1093 gene gene NN 1093 1094 . . . 1095 1100 These these DT 1101 1108 results result NNS 1109 1118 indicated indicate VBD 1119 1123 that that IN 1124 1135 salicylates salicylate NNS 1136 1145 inhibited inhibit VBD 1146 1149 LPS LPS NNP 1150 1159 induction induction NN 1160 1162 of of IN 1163 1165 TF TF NNP 1166 1170 gene gene NN 1171 1184 transcription transcription NN 1185 1187 in in IN 1188 1197 monocytic monocytic JJ 1198 1203 cells cell NNS 1204 1206 by by IN 1207 1217 preventing prevent VBG 1218 1225 nuclear nuclear JJ 1226 1239 translocation translocation NN 1240 1242 of of IN 1243 1252 c-Rel/p65 c-rel/p65 NN 1253 1265 heterodimers heterodimer NNS 1265 1266 . . . 1267 1270 The the DT 1271 1279 clinical clinical JJ 1280 1288 benefits benefit NNS 1289 1291 of of IN 1292 1303 salicylates salicylate NNS 1304 1306 in in IN 1307 1310 the the DT 1311 1320 treatment treatment NN 1321 1323 of of IN 1324 1331 several several JJ 1332 1340 diseases disease NNS 1340 1341 , , , 1342 1351 including include VBG 1352 1367 atherosclerosis atherosclerosis NN 1368 1371 and and CC 1372 1382 rheumatoid rheumatoid JJ 1383 1392 arthritis arthritis NN 1392 1393 , , , 1394 1397 may may MD 1398 1400 be be VB 1401 1408 related relate VBN 1409 1411 to to TO 1412 1417 their their PRP$ 1418 1425 ability ability NN 1426 1428 to to TO 1429 1435 reduce reduce VB 1436 1444 monocyte monocyte NN 1445 1449 gene gene NN 1450 1460 expression expression NN 1460 1461 . . .